Bosutinib (SKI-606)
-
- Application
- Inhibition Assay (InhA), Functional Studies (Func)
- Purpose
- Bosutinib is a Bcr-Abl kinase inhibitor for the treatment of Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML). Compared to other tyrosine kinase inhibitors, it has a more favourable hematologic toxicity profile. FDA approved on September 4, 2012.
- Characteristics
-
Tradename: Bosutinib
Source of Compound: synthetic
Target: MAPK inhibitor,Src inhibitor,Bcr-Abl inhibitor,CaMK inhibitor,CDK inhibitor
Receptor: MAPKK2, MAPKKK2,ABL1, Lyn, HCK, Src,Breakpoint cluster region protein(BCR),Bcr-Abl ,CaMK,CDK 2
- Purification
- All the products are sent with COA, HPLC and NMR inspection report to guarantee the quality.
- Purity
- 99 %
- Formula
- C26H29Cl2N5O3
- Solubility
- Soluble in DMSO
-
-
- Application Notes
- Optimal working dilution should be determined by the investigator.
- Restrictions
- For Research Use only
-
- Format
- Solid
- Storage
- -20 °C
- Storage Comment
-
For the majority of compounds, they could be dissolved in DMSO or other organic solvent.
Their stock solution can be stored at -20°C for up to 3 months and aliquoted for sampling convenience.
Several freeze/thaw cycles should not damage the activity of our small molecule products.
However, in many instances the aqueous solutions of some compounds need to be made fresh and cannot be stored. For these compounds, their solution should be prepared just before use and stored no longer than 24 hours. - Expiry Date
- 24 months
-
- Background
- Cell cycle/Checkpoint,MAPK Signaling,Neuroscience,Tyrosine Kinase/Adaptors
- Molecular Weight
- 530.45 g/mol
- CAS-No
- 380843-75-4
-